18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of prostate cancer * Biochemical recurrence was defined as a PSA of 0.2 or more ng/mL measured more than 6 weeks after prostatectomy or a PSA of 2 or more ng/mL rise above nadir following radiation therapy (ASTRO Phoenix consensus definition) * Age ≥ 18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%) * Ability to understand and willingness to sign a written informed consent document * Willing to comply with clinical trial instructions and requirements Exclusion Criteria: * History of another active malignancy within 3 years, other than basal cell and squamous cell carcinoma of the skin * Presence of prostate brachytherapy implants unless approved by the PI * Administration of another radioisotope within five physical half-lives of trial enrollment * Radiation or chemotherapy within 2 weeks prior to trial enrollment * Estimated glomerular filtration rate (eGFR) \< 15 ml/mmol * Serum total bilirubin \> 3 times the upper limit of normal * Aspartate transaminase (AST) or alanine aminotransferase (ALT) \> 5 times the upper limit of normal * Inadequate venous access * Claustrophobia or any other condition that would preclude PET imaging * Patients must not be receiving ADT except per criteria directly below. Patients who received in the past must have a serum testosterone that is recovered to at least 100 ng/dL. * Patients who have been on ADT +/- novel hormonal agent (NHA) and developed M0 CRPC